Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Last Updated: March 21, 2023

Investigational Drug Information for Vistusertib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Vistusertib?

Vistusertib is an investigational drug.

There have been 14 clinical trials for Vistusertib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are one hundred and fourteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Vistusertib
TitleSponsorPhase
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)National Cancer Institute (NCI)Phase 1
Phase II Trial of Vistusertib´╝łAZD2014´╝ë Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2

See all Vistusertib clinical trials

Clinical Trial Summary for Vistusertib

Top disease conditions for Vistusertib
Top clinical trial sponsors for Vistusertib

See all Vistusertib clinical trials

US Patents for Vistusertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vistusertib See Plans and Pricing Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) See Plans and Pricing
Vistusertib See Plans and Pricing Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors KuDOS Pharmaceuticals Limited (London, GB) See Plans and Pricing
Vistusertib See Plans and Pricing 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) See Plans and Pricing
Vistusertib See Plans and Pricing Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
Vistusertib See Plans and Pricing Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vistusertib

Drugname Country Document Number Estimated Expiration Related US Patent
Vistusertib Australia AU2014348657 2033-11-13 See Plans and Pricing
Vistusertib Australia AU2017245411 2033-11-13 See Plans and Pricing
Vistusertib Australia AU2019246853 2033-11-13 See Plans and Pricing
Vistusertib Brazil BR112016010716 2033-11-13 See Plans and Pricing
Vistusertib Canada CA2929181 2033-11-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.